David Richard Walwyn

Prof. David Richard Walwyn

orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1983 in Carbohydrate Research
Verified
Journal Article
Closed access
SCShirley C. Churms
Shirley C. Churms
EMEdwin H. Merrifield
Edwin H. Merrifield
ASAlistair M. Stephen
Alistair M. Stephen
DWDavid Richard Walwyn
David Richard Walwyn
APAlfred Polson
Alfred Polson
NCNino Costa
Nino Costa

25 October 2014 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
DWDavid Richard Walwyn
David Richard Walwyn
SHSuzanne M. Huddy
Suzanne M. Huddy
Edward Peter RybickiEdward Peter Rybicki
Edward Peter Rybicki

27 March 2018 in Health Research Policy and Systems
Verified
Journal Article
Open access
PDF file
DWDavid Richard Walwyn
David Richard Walwyn
ANAdolph T. Nkolele
Adolph T. Nkolele
Public–private partnerships (PPPs), widely used as a means of leveraging the skills, expertise and resources of the private sector to mutual advantage, were similarly adopted by South Africa to support public sector delivery. This study has evaluated one such partnership, namely the Biovac Institute, which was established in 2003 to cover vaccine research and development, manufacturing, and supply. The initiative was highly unusual given that it attempted to combine all three aspects in a single PPP. The research has followed a concurrent mixed methods approach. In the quantitative study, data for prices and product volumes were extracted from secondary data sources and used to calculate the economic cost and value-for-money of the PPP. Simultaneously, a qualitative study was undertaken in which a number of key stakeholders were interviewed using a semi-structured questionnaire on their perceptions of the PPP’s value. The institute earns a premium on the procurement cost of a broad range of vaccines required by the South African National Department of Health for its immunisation programme, the net value of which was US$85.7 million over the period 2010 to 2014. These funds were used to finance the institute’s operations, including vaccine research, distribution and quality control. Capital expenditure to support the establishment of facilities for laboratory testing, packaging and labelling, filling, formulation and, finally, active pharmaceutical ingredient manufacture, approximately US$40 million in total, had to be secured through loans and grants. According to the respondents in the qualitative survey, the principal benefit of the PPP has been the uninterrupted supply of vaccines and the ability to respond quickly to vaccine shortages. The main disadvantages appear to have been a slow and ineffectual establishment of a vaccine manufacturing centre and, initially, a limited ability to negotiate highly competitive vaccine prices. Overall, it is concluded that a positive value-for-money has been achieved and the institute has been of significant public benefit. Relationships of this nature can be used to achieve public health goals, but need to be realistic about timeframes, costs and the limitations of relational governance in ensuring that complex programmatic outcomes are achieved. It is recommended that a more incremental approach, with clearer contractual goals, penalties and incentives, is adopted in attempting initiatives aimed at the localisation of manufacturing technology by leveraging public procurement.


1 March 2013 in African Journal of AIDS Research
Verified
Journal Article
Closed access
DWDavid Richard Walwyn
David Richard Walwyn
Registered in 2001, tenofovir disoproxil fumarate (TDF) has quickly become a mainstay of first line regimens for the treatment of HIV. Initially only available in developed countries at a cost of US$5 000 per person per year (ppy), Gilead's Access Programme (GAP) has extended the use of the product to 2.4 million patients in low and middle income countries. The programme has two components: distribution of the branded product at reduced prices and licensing partnerships with generic manufacturers. The licensing partnerships now supply 75% of the market by volume, at a treatment cost of US$57 ppy (1% of the branded cost). From Gilead's perspective, GAP must be considered a huge success. It has enabled the company to maintain high prices in developed countries whilst reducing its input costs and deflecting criticism of its failure to provide essential medicines for the poor, hence risking the possibility of compulsory licensing. Over the period 2001 to 2011, TDF in its various forms has generated for Gilead more than US$31 billion revenue at a gross margin of 80%, equivalent to a gross profit of US$25 billion. Analysis of the TDF value chain, from preparation of the active pharmaceutical ingredient (API) to sale of the formulated product, shows that manufacturing margins are highly skewed in favour of the originator, with the latter's profit being US$3.2 billion vs. US$4 million for API manufacturers and US$39 million for formulators (2011). The data argues for a more rational approach to drug pricing including possible regulation in developed countries and more sustainable margins for the generic producers.

9 December 2019 in Journal of Manufacturing Technology Management
Verified
Journal Article
Closed access
DWDavid Richard Walwyn
David Richard Walwyn
ABAndreas Bertoldi
Andreas Bertoldi
CGChristian Gable
Christian Gable
Purpose: Hydrogen fuel cells could play an important role in meeting the challenges of the Two Degrees Scenario. The purpose of this paper is to review the development of this technology in South Africa with the aim of understanding how the country can transform its existing socio-technical systems and act to support a hydrogen-based technological innovation system (TIS). Design/methodology/approach: A mixed methods approach has been followed in this study. Secondary data analysis was used initially to build a profile of South Africa’s present energy system, followed by a stakeholder survey of the emerging hydrogen economy. Respondents were selected based on a convenience/snowball sampling approach and were interviewed using a semi-structured questionnaire, covering opportunities for South Africa in the global hydrogen economy; sources of competitive advantage; the present phase of development; the maturity of each function and the main weaknesses within the TIS; and finally the appropriate policy instrument to remedy the weakness and/or maximise opportunities for local companies. Findings: The research has shown that the hydrogen economy is still at a pre-competitive level and requires ongoing government support to ensure an energy transition is realised. In particular, it is important that niche experimentation, a proven strategy in respect of successful sustainability transitions, is further pursued. Importantly, the net cost of hydrogen-based transportation, which is still several times larger than the cost of transport based on the internal combustion engine (ICE), must be reduced, especially in the key applications of public transport and underground vehicles. Furthermore, the development of digital technologies to manage supply fluctuations in energy grids must be accelerated. Originality/value: The South Africa economy will be severely affected by the replacement of the ICEs with battery electric vehicles due to the country’s reliance on ICEs for platinum demand. Fuel cells represent a new market for platinum but the hydrogen TIS is still at a vulnerable point in its development; without policy support, it will not contribute to a successful socio-technical transformation, nor provide an alternative outlet for platinum.